Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker IMNN · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard… NCT06915025 · Epithelial Ovarian Cancer, Ovarian Cancer IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol… | IMNN Imunon | Phase 3 | Recruiting | 500 | Oct 31, 2032 | Registry ↗ |
| Nov 12, 2026 | Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian,… NCT05739981 · Ovarian Cancer, Fallopian Tube Cancer Paclitaxel, Carboplatin | IMNN Imunon | Phase 1/2 | Recruiting | 30 | Jun 30, 2027 | Registry ↗ |
| May 4, 2026 | Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) NCT03393884 · Epithelial Ovarian Cancer, Fallopian Tube Cancer IMNN-001, Carboplatin | IMNN Imunon | Phase 1/2 | Active, not recruiting | 130 | Jul 25, 2024 | Registry ↗ |
| Jul 23, 2025 | Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously… NCT06283459 · SARS CoV 2 Infection IMNN-101 | IMNN Imunon | Phase 1/2 | Completed | 24 | Mar 7, 2025 | Registry ↗ |
| Oct 2, 2024 | Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo i… NCT02480374 · Epithelial Ovarian Cancer, Fallopian Tube Cancer IMNN-001 | IMNN Imunon | Phase 1 | Completed | 18 | May 2017 | Registry ↗ |
| Aug 20, 2024 | Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular… NCT02112656 · Hepatocellular Carcinoma ThermoDox, Dummy infusion | IMNN Imunon | Phase 3 | Completed | 554 | Apr 27, 2020 | Registry ↗ |
| May 3, 2024 | Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcin… NCT00617981 · Hepatocellular Carcinoma ThermoDox, 5% Dextrose Solution | IMNN Imunon | Phase 3 | Completed | 701 | Jan 2013 | Registry ↗ |
| Oct 13, 2022 | Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastat… NCT01464593 · Colon Cancer Liver Metastasis Lyso-Thermosensitive Liposomal Doxorubicin, 5% Dextrose Sol… | IMNN Imunon | Phase 2 | Terminated | 2 | May 2013 | Registry ↗ |
| Apr 7, 2022 | Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer Patients NCT02850419 · Breast Cancer ThermoDox (Thermally Sensitive Liposomal Doxorubicin), Radi… | IMNN Imunon | Phase 2 | Withdrawn | 0 | Dec 2019 | Registry ↗ |
| Feb 7, 2019 | A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic T… NCT00441376 · Hepatocellular Carcinoma, Liver Neoplasms ThermoDox | IMNN Imunon | Phase 1 | Completed | 30 | Oct 2008 | Registry ↗ |
| Feb 7, 2017 | MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Me… NCT01640847 · Painful Bone Metastases, Breast Carcinoma High Intensity Focused Ultrasound (HIFU) in combination wit… | IMNN Imunon | Phase 2 | Withdrawn | 0 | Jun 2013 | Registry ↗ |
| Jan 30, 2017 | Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at… NCT00826085 · Breast Cancer ThermoDox in combination with Microwave Hyperthermia (heat) | IMNN Imunon | Phase 1/2 | Completed | 17 | Dec 2015 | Registry ↗ |
12 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 16, 2026, 1:26 AM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances